ABSTRACT
Hypertension is one of the strongest modifiable risk factors for cardiovascular and kidney disease and has been identified as the leading risk factor for mortality. The reduction of blood pressure lower than 130/85 mmHg provides additional benefits regarding both protection of organs and cardiovascular mortality. It suppresses the effects of angitensin II at its receptors, thereby blocking the rennin-angiotensin system. The rennin-angiotensin system plays a crucial role in the control of blood pressure, and in particular it is felt to play crucial role in hypertension. The objective of this double-blind, comparative study evaluating efficacy and biochemical effects of optimized Losartan Potassium 50mg [F-6] as monotherapy in adult patient with essential hypertension. Double-blind, comparative study. This study was conducted at the Department of Biochemistry, University of Karachi from January 2010 to August 2010. This was multicenter randomized, double-blind, comparative study. Patients were randomized to receive once Losartan Potassium 50mg [F-6] daily for 8 weeks and at the end of study efficacy and biochemical evaluation was done. The patients treated with optimized Losartan potassium [F-6] alone, blood pressure reduction was lower, although significant; reaching values of 140.9 +/- 11.3 / m88.9 +/- 5.5 mmHg [p < 0.05 versus Placebo] by the end of eight weeks of treatment.. No significant variation of blood glucose was observed and different parameters of lipid profile were also observed during the eight weeks of treatment with antihypertensive regimen used. Thus, the drug regimens used may be considered neutral as regards glucose and plasma lipid metabolism profile because drug used at low doses. We can suggest that the high antihypertensive efficacy, good tolerability and no biochemical effects of the optimized Losartan potassium [F-6] it is an excellent option for the treatment of hypertension in a wide range of hypertensive patients, with a high potential to reduce cardiovascular risks
ABSTRACT
The objective of this double-blind, comparative study evaluating efficacy and biochemical effects of optimized Valsartan 80mg [F-3] as monotherapy in adult patient with essential hypertension. Double-blind, comparative study. This study was conducted at the Department of Biochemistry, University of Karachi from January 2011 to September 2011. This was multicenter randomized, double-blind, comparative study. Patients were randomized to receive once Valsartan [F-3] daily for 8 weeks and at the end of study efficacy and biochemical evaluation was done. The patients treated with optimized Valsartan 80mg [F-3] alone, blood pressure reduction was lower, although significant; reaching values of 140.9 +/- 11.3 / m88.9 +/- 5.5 mmHg [p < 0.05 versus Placebo] by the end of eight weeks of treatment. . No significant variation of blood glucose was observed and different parameters of lipid profile were also observed during the eight weeks of treatment with antihypertensive regimen used. Thus, the drug regimens used may be considered neutral as regards glucose and plasma lipid metabolism profile because drug used at low doses. We can suggest that the high antihypertensive efficacy, good tolerability and no biochemical effects of the optimized Valsartan 80mg [F-3] it is an excellent option for the treatment of hypertension in a wide range of hypertensive patients, with a high potential to reduce cardiovascular risks
ABSTRACT
The reduction of blood pressure lower than 130/85 mmHg provides additional benefits regarding both protection of organs and cardiovascular mortality. Amlodipine is a calcium channel-blocking agent with vasodilator activity and Ramipril is ACE inhibitor. The objective of this double-blind, comparative study evaluating the biochemical effects of Amlodipine 5 mg and Ramipril 1.25 mg in combination and as monotherapy in adult patient with essential hypertension, double-blind, comparative study. This study was conducted at the department of Biochemistry, University of Karachi from December 2010 to September 2011. This was multicenter randomized, double-blind, comparative study. Patients were randomized to receive Amlodopine [5 mg] once daily, Ramipril [1.25 mg] once daily and combination of amlodipine 5 mg with Ramipril 1.25 mg once daily for 8 weeks and at the end of study biochemical evaluation was done. In the patients treated with combination of Amlodipine 5 mg and Ramipril 1.25 mg tablets showed synergetic effect and no significant biochemical effects. We can suggest that good tolerability and no biochemical and hematological effects of combination of Amlodipine 5 mg and Ramipril 1.25 mg to formulate in a single dosage forms [tablet] because it is an excellent option for the treatment of hypertension in a wide range of hypertensive patients, with a high potential to reduce cardiovascular risks
ABSTRACT
Management of congenital nasolarcimal duct obstruction with massaging and probing without general anesthesia. Retrospective as well as prospective study. This study was carried out in the out patients department of DHQ teaching hospital charsadda for the period of nine months between 2010 and 2011. Total number of children/infants was fifty. All suspected patients were carefully examined and divided into two groups. Statistically analysis was done by student's "t" table. When results were summed up and test parameters were separated it was seen that the success rate with sample massaging and use of topical antibiotic was 90% at the end of nine months. Five infants improved with single probing. Infantile epiphora due to nasolacrimal duct obstruction generally cured with auto canalization/ massaging with topical antibiotics at the age of 5 months. The 2[nd] thing in this study that we can use topical anesthetic agent instead of exposing the infant to the hazard and the complication of general anesthesia
Subject(s)
Humans , Female , Male , Lacrimal Duct Obstruction/congenital , Massage , Anesthesia, GeneralABSTRACT
An adequate blood pressure is a treatment of hypertension and it is the risk of cardiovascular morbidity and mortality so proper therapy is essential. Combination therapy of amlodipine plus atorvastatin improved vascular compliance, an indicator of structural and functional vascular changes, and the beneficial effect on small arteries appeared to be more than additive. This study aimed to evaluate the efficacy and biochemical effects of once-daily optimized Amlodpine/Atorvastatin 5/10 mg [F-6] versus placebo. placebo-controlled, comparative study. This study conducted in the Department of Biochemistry, University of Karachi from July 2010 to January 2011. This was multicenter, randomized, placebo-controlled, comparative study. Patients were selected from different hospitals of Orangi Town Karachi and samples were analyzed in the department of Biochemistry, University of Karachi. Patients were randomized to receive optimized Amlodpine/Atorvastatin 5/10 mg [F-6] once daily and Placebo once daily for 8 weeks. The efficacy and biochemical effects variables were change from baseline at the end of study which was evaluated. In the patients treated with optimized Amlodipine /Atorvastatin 5/10mg tablets' [F-6] alone, blood pressure reduction was lower, although significant, reaching values of 136.9 +/- 10.7 / 88.2 +/- 6.3 mmHg [p < 0.05 versus Placebo] by the end of eight weeks of treatment. Thus, the drug regimens used may be considered neutral as regards glucose and significantly reduce LDL-Cholesterol. Due to the high antihypertensive efficacy and hypolipidemic and no biochemical effects of the optimized Amlodipine/Atorvastatin 5/10 mg [F-6] it is an excellent option for the treatment of hypertension and hyperlipidemia patients, with a high potential to reduce cardiovascular risks